Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346083 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Betrixaban in Pediatric Participants
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03346083 is a Phase 1 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT03346083, a Phase 1 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).
Interventions
- DRUG Betrixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2019-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346083
The ClinicalTrials.gov registry entry for NCT03346083 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Betrixaban is the first listed.
NCT03346083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346083 about?
NCT03346083 is a clinical study titled "Study Evaluating Betrixaban in Pediatric Participants". This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).
What is the current status of trial NCT03346083?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-07-13. Estimated completion is 2019-10-08.
What interventions are being tested in trial NCT03346083?
The interventions under investigation include: Betrixaban (DRUG).
Who is sponsoring clinical trial NCT03346083?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.